Daan P. Hurkmans - Concepedia

Author

Daan P. Hurkmans

Erasmus MC ORCID

Also Known As

D Hurkmans, D. Hurkmans, D.P. Hurkmans, Daan Hurkmans, Daan P Hurkmans, Daan P. Hurkmans, Daniel P. Hurkmans

Publications

991

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Erasmus University Rotterdam Amphia Ziekenhuis Leiden University Medical Center

About

Daan P. Hurkmans is an author at Erasmus MC specializing in lung cancer, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	178
2	Cancer Therapeutics	2	2	178
3	Lung Cancer	2	2	178
4	Oncology	2	2	178
5	Pharmacology	1	1	107

Daan P. Hurkmans

Publications

929

Citations

H-Index

Page 1

	Year	Citations
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients Luca Cantini, Federica Pecci, Daan P. Hurkmans, European Journal of Cancer High-intensity StatinsMedicinePharmacologyPd-1 InhibitorsImproved Clinical Activity	2020	107
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients Daan P. Hurkmans, Merian E. Kuipers, Jasper Smit, Cancer Immunology Immunotherapy	2020	100
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients Edwin A. Basak, Jan W.M. van der Meer, Daan P. Hurkmans, Thyroid	2020	86
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Journal for ImmunoTherapy of Cancer	2019	82
Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer Edwin A. Basak, Stijn L.W. Koolen, Daan P. Hurkmans, European Journal of Cancer Non–small-cell Lung CancerMedicineCancer ManagementImmune Checkpoint InhibitorNivolumab Exposure	2019	71
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Journal for ImmunoTherapy of Cancer	2020	70
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab André Kunert, Edwin A. Basak, Daan P. Hurkmans, Journal for ImmunoTherapy of Cancer	2019	55
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma Jinfeng Cao, Niels J. Brouwer, Kate Richards, Oncotarget	2017	50
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen Koen G. A. M. Hussaarts, Daan P. Hurkmans, Esther Oomen‐de Hoop, Cancers	2019	47
Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma Daan P. Hurkmans, Christina Jensen, Stijn L.W. Koolen, Journal for ImmunoTherapy of Cancer	2020	44

Page 1